Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients
“The quality of what Pharmacy Management is putting on is simply streets ahead of anything else I’m seeing at the moment. Keep up the good work!”
Noel Wicks, Managing Director, Right Medicine Pharmacy Ltd, Stirling
|Satellite||Does PEGASUS need a COMPASS to find optimal medical management? – reviewing options in high risk CVD patients|
|Speakers||Paul Wright (Lead Cardiac Pharmacist - Cardiac Pharmacy Department, Barts Heart Centre, Barts Health NHS Trust)|
This session will touch of current practice for treatment options for those at high risk of CVD. We will explore previous trial data looking at extending DAPT therapy and explore new options – predominantly data for rivaroxaban 2.5mg twice daily (in the COMPASS trial) and from ticagrelor 60mg twice daily (from the PEGASUS trial). Finally we will explore options on how these strategies could be implemented at a local level.
Advanced level – knowledge of ACS and current treatment strategies required